Evidence map›Paper›PMID 29104752›Full record

ArticleJRSM cardiovascular disease

Combined analysis of the safety of intra-coronary drug delivery during primary percutaneous coronary intervention for acute myocardial infarction: A study of three clinical trials.

Krishnaraj S Rathod, Stephen Hamshere, Rayomand S Khambata, Mervyn Andiapen, Mark Westwood, Anthony Mathur, Amrita Ahluwalia, Daniel A Jones

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JRSM cardiovascular disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06850831 (Effect of Intracoronary N-Acetylcysteine on Malondialdehyde, Interleukin-6, High Sensitivity Troponin I, Caspase-3, Global Longitudinal Strain, and 6-Minutes Walking Test in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06850831 phase2completednot on this map

Effect of Intracoronary N-Acetylcysteine on Malondialdehyde, Interleukin-6, High Sensitivity Troponin I, Caspase-3, Global Longitudinal Strain, and 6-Minutes Walking Test in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

TypeinterventionalSponsordr. Ahmad Yasa, Sp.JP, Subsp.K.I.(K), M.Kes, FIHA, FasCC, FARan2025 to 2025Enrolled70ConditionsSTEMI - ST Elevation Myocardial Infarction (MI), Primary PCI - STEMIArmsAntipac
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Krishnaraj S RathodWilliam Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, London, UK.
Stephen HamshereDepartment of Cardiology, Barts Health NHS Trust, London, UK.
Rayomand S KhambataWilliam Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, London, UK.
Mervyn AndiapenDepartment of Cardiology, Barts Health NHS Trust, London, UK.
Mark WestwoodDepartment of Cardiology, Barts Health NHS Trust, London, UK.
Anthony MathurWilliam Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, London, UK.
Amrita AhluwaliaWilliam Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, London, UK.
Daniel A JonesWilliam Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, London, UK.
Barts Health NHS Trust · GBQueen Mary University of London · GBWilliam Harvey Research Institute · GB

Funding

Department of Health DRF-2014-07-008
6 · The paper itself

Abstract

backgroundThe local injection of novel cardioprotective study drugs prior to percutaneous coronary intervention could cause embolisation of thrombus, resulting in increased reperfusion injury and subsequent infarct size. The aim of this study was to assess the safety of the delivery of an intracoronary therapy delivered during primary percutaneous coronary intervention for acute myocardial infarction prior to the re-establishment of thrombolysis in myocardial infarction III flow.

methodsOne hundred sixty-seven patients with acute myocardial infarction successfully reperfused through primary percutaneous coronary intervention and undergoing Cardiac MRI within the first week after reperfusion were studied. Patients either underwent the delivery of an intracoronary agent (IMP or placebo) prior to balloon dilatation (

resultsBaseline characteristics were similar between the two groups. There were a similar number of successful procedures (IC IMP 75 (93.8%) vs. No IMP 114, (97.4%),

conclusionThe local intracoronary infusion of potential cardioprotective agents prior to the restoration of TIMI flow in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction appears to be safe and does not increase microvascular damage. This route should be considered when testing novel cardioprotective agents.

Indexed as

Acute coronary syndromescardiologycardiovascular pharmacologycatheter-based coronary interventions: stentsCT and MRIdiagnostic testingetiologytreatment

Identifiers

PMID29104752
PMCPMC5562348
OpenAlexW2746256882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.